Ilaria Meynet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilaria Meynet has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Sakis Themistoclakis
Division of Cardiology, Hospital dell’Angelo , Mestre-Venice
4 shared publications - Giuseppe Boriani
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, 41124 Modena, Italy
3 shared publications - Martina Nesti
Department of Electrophysiology, Fondazione Toscana Gabriele Monasterio , Pisa
3 shared publications - Matteo Anselmino
Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Department of Medical Sciences, University of Turin, Turin, Italy
3 shared publications - Maurizio Malacrida
Boston Scientific
3 shared publications - Antonio D'ONofrio
Unità Operativa di Elettrofisiologia, studio e terapia delle aritmie, Monaldi Hospital, Naples, Italy (A.D.).
2 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (5)
Sedation Strategies, Drugs, and Protocols Used in Catheter Ablation of Atrial Fibrillation: A Focused Review
Catheter ablation is the mainstay of rhythm control in atrial fibrillation (AF), and its use is steadily increasing worldwide. To optimize procedural safety and efficacy, an appropriate sedation or anesthesia regimen is essential, ensuring adequate analgesia and a stable respiratory pattern while minimizing patient movement. However, the optimal sedation strategy remains a matter of debate, with approaches ranging from general anesthesia to deep or conscious sedation. Since anesthesiologists administer general anesthesia, attention focuses on hypnotics, defined as drugs that induce and/or maintain sleep by depressing the central nervous system, and analgesics. In many centers, these agents are administered by electrophysiology laboratory staff in accordance with local regulations and institutional protocols, which vary among countries. This warrants caution, as individual responses to commonly combined agents are unpredictable and may result in deeper-than-intended sedation. Therefore, respiratory or hemodynamic support may become necessary in selected patients. Notably, protocols incorporating hypnotic communication have also been proposed and implemented. The selection of sedation and analgesia strategies for AF ablation has become increasingly important for balancing patient safety, procedural effectiveness, and resource utilization. The approach should be individualized based on patient characteristics, procedural complexity, energy source, institutional resources, and the relevant national regulatory framework.
- 26 May 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (5)
Open AccessSedation Strategies, Drugs, and Protocols Used in Catheter Ablation of Atrial Fibrillation: A Focused Review
Catheter ablation is the mainstay of rhythm control in atrial fibrillation (AF), and its use is steadily increasing worldwide. To optimize procedural safety and efficacy, an appropriate sedation or anesthesia regimen is essential, ensuring adequate analgesia and a stable respiratory pattern while minimizing patient movement. However, the optimal sedation strategy remains a matter of debate, with approaches ranging from general anesthesia to deep or conscious sedation. Since anesthesiologists administer general anesthesia, attention focuses on hypnotics, defined as drugs that induce and/or maintain sleep by depressing the central nervous system, and analgesics. In many centers, these agents are administered by electrophysiology laboratory staff in accordance with local regulations and institutional protocols, which vary among countries. This warrants caution, as individual responses to commonly combined agents are unpredictable and may result in deeper-than-intended sedation. Therefore, respiratory or hemodynamic support may become necessary in selected patients. Notably, protocols incorporating hypnotic communication have also been proposed and implemented. The selection of sedation and analgesia strategies for AF ablation has become increasingly important for balancing patient safety, procedural effectiveness, and resource utilization. The approach should be individualized based on patient characteristics, procedural complexity, energy source, institutional resources, and the relevant national regulatory framework.
- Open Access
- 26 May 2026
- Vol. 27 (5)
Sedation Strategies, Drugs, and Protocols Used in Catheter Ablation of Atrial Fibrillation: A Focused Review
Catheter ablation is the mainstay of rhythm control in atrial fibrillation (AF), and its use is steadily increasing worldwide. To optimize procedural safety and efficacy, an appropriate sedation or anesthesia regimen is essential, ensuring adequate analgesia and a stable respiratory pattern while minimizing patient movement. However, the optimal sedation strategy remains a matter of debate, with approaches ranging from general anesthesia to deep or conscious sedation. Since anesthesiologists administer general anesthesia, attention focuses on hypnotics, defined as drugs that induce and/or maintain sleep by depressing the central nervous system, and analgesics. In many centers, these agents are administered by electrophysiology laboratory staff in accordance with local regulations and institutional protocols, which vary among countries. This warrants caution, as individual responses to commonly combined agents are unpredictable and may result in deeper-than-intended sedation. Therefore, respiratory or hemodynamic support may become necessary in selected patients. Notably, protocols incorporating hypnotic communication have also been proposed and implemented. The selection of sedation and analgesia strategies for AF ablation has become increasingly important for balancing patient safety, procedural effectiveness, and resource utilization. The approach should be individualized based on patient characteristics, procedural complexity, energy source, institutional resources, and the relevant national regulatory framework.
- 26 May 2026
- Vol. 27 (5)
Open AccessSedation Strategies, Drugs, and Protocols Used in Catheter Ablation of Atrial Fibrillation: A Focused Review
Catheter ablation is the mainstay of rhythm control in atrial fibrillation (AF), and its use is steadily increasing worldwide. To optimize procedural safety and efficacy, an appropriate sedation or anesthesia regimen is essential, ensuring adequate analgesia and a stable respiratory pattern while minimizing patient movement. However, the optimal sedation strategy remains a matter of debate, with approaches ranging from general anesthesia to deep or conscious sedation. Since anesthesiologists administer general anesthesia, attention focuses on hypnotics, defined as drugs that induce and/or maintain sleep by depressing the central nervous system, and analgesics. In many centers, these agents are administered by electrophysiology laboratory staff in accordance with local regulations and institutional protocols, which vary among countries. This warrants caution, as individual responses to commonly combined agents are unpredictable and may result in deeper-than-intended sedation. Therefore, respiratory or hemodynamic support may become necessary in selected patients. Notably, protocols incorporating hypnotic communication have also been proposed and implemented. The selection of sedation and analgesia strategies for AF ablation has become increasingly important for balancing patient safety, procedural effectiveness, and resource utilization. The approach should be individualized based on patient characteristics, procedural complexity, energy source, institutional resources, and the relevant national regulatory framework.
- Open Access
- 6 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (5)
Machine learning prediction of outcome following pulsed-field atrial fibrillation ablation: patient selection and risk factors
Background: Despite being the most effective option for maintaining sinus rhythm, atrial fibrillation (AF) catheter ablation reaches few patients. For this reason, identifying candidates with the highest likelihood of success or individualizing counselling to a specific patient to improve procedural outcome could enhance clinical benefits and cost-effectiveness. Objective: To integrate machine learning (ML) into an outcome prediction model based on a large cohort of AF patients undergoing pulsed field ablation (PFA). Methods: Consecutive AF patients undergoing transcatheter PFA between June 2022 and December 2024 were prospectively enrolled in the ATHENA registry. All procedures were performed with a penta-splines 12F over-the-wire PFA catheter (FARAWAVE™, Boston Scientific). Clinical and procedural variables were collected to train five predictive models estimating 1 year arrhythmic recurrence; model interpretability was assessed using SHAP (SHapley Additive exPlanations) analysis. Results: The study included 1688 AF patients with a median follow-up of 365 days (interquartile range 202-393), arrhythmic recurrence occurred in 314 patients (18.6%). The Boruta algorithm identified diagnosis-to-ablation time (DAT), CHA₂DS₂-VASc score, age, and body mass index (BMI) as most significant predictors. Among the five ML models developed to predict 1 year arrhythmic recurrence probability, Random Forest achieved the best performance (AUC = 0.75, 95% CI 0.69-0.82). SHAP analysis confirmed DAT, BMI, and indexed left atrial volume as major contributors to recurrence. Conclusion: This is the first ML model exclusively trained and validated on AF patients undergoing PFA providing actionable insights for personalized treatment planning. Routine use of the model holds the potential to optimize patient selection and improve procedural outcome, supporting individualized counselling and outcome-driven care pathways, moving from static to interactive risk prediction. Clinical Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/ Identifier: NCT05617456
- 6 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (5)
Open AccessMachine learning prediction of outcome following pulsed-field atrial fibrillation ablation: patient selection and risk factors
Background: Despite being the most effective option for maintaining sinus rhythm, atrial fibrillation (AF) catheter ablation reaches few patients. For this reason, identifying candidates with the highest likelihood of success or individualizing counselling to a specific patient to improve procedural outcome could enhance clinical benefits and cost-effectiveness. Objective: To integrate machine learning (ML) into an outcome prediction model based on a large cohort of AF patients undergoing pulsed field ablation (PFA). Methods: Consecutive AF patients undergoing transcatheter PFA between June 2022 and December 2024 were prospectively enrolled in the ATHENA registry. All procedures were performed with a penta-splines 12F over-the-wire PFA catheter (FARAWAVE™, Boston Scientific). Clinical and procedural variables were collected to train five predictive models estimating 1 year arrhythmic recurrence; model interpretability was assessed using SHAP (SHapley Additive exPlanations) analysis. Results: The study included 1688 AF patients with a median follow-up of 365 days (interquartile range 202-393), arrhythmic recurrence occurred in 314 patients (18.6%). The Boruta algorithm identified diagnosis-to-ablation time (DAT), CHA₂DS₂-VASc score, age, and body mass index (BMI) as most significant predictors. Among the five ML models developed to predict 1 year arrhythmic recurrence probability, Random Forest achieved the best performance (AUC = 0.75, 95% CI 0.69-0.82). SHAP analysis confirmed DAT, BMI, and indexed left atrial volume as major contributors to recurrence. Conclusion: This is the first ML model exclusively trained and validated on AF patients undergoing PFA providing actionable insights for personalized treatment planning. Routine use of the model holds the potential to optimize patient selection and improve procedural outcome, supporting individualized counselling and outcome-driven care pathways, moving from static to interactive risk prediction. Clinical Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/ Identifier: NCT05617456
- Open Access
- 17 March 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Pulsed field ablation for atrial fibrillation in patients with heart failure: insight from the ATHENA registry
Aims: Data on pulsed-field ablation (PFA) for atrial fibrillation (AF) in patients with heart failure (HF) are limited. To evaluate clinical outcomes of PFA in patients with AF and HF, stratified by HF subtype. Methods and Results: Consecutive patients undergoing first-time pentaspline PFA within the ATHENA registry were analyzed. Patients were stratified into three groups: no HF, HF with preserved ejection fraction (HFpEF, LVEF ≥50%), and HF with mildly reduced or reduced EF (HFmrEF/rEF, LVEF 30 s after a 2-month blanking period. AAD use was left to physician discretion. Among 1,224 patients included (68.5% with paroxysmal AF and 31.5% with persistent AF), 176 (14.4%) had HF: 40 (3.3%) with HFpEF and 136 (11.1%) with HFmrEF/rEF. The Kaplan-Meier estimated freedom from any atrial arrhythmias at 1-year follow-up was 79.9%, with higher rate in the no-HF group (81.0%) vs the HF group (73.3%, HR = 1.5, 95% CI: 1.1–2.1, P = 0.0133). Considering separately paroxysmal and persistent AF form, paroxysmal AF patients with no sign of HF showed significantly higher freedom from atrial arrhythmias (82.2%) than patients with HF (68.6%, 2.0, 1.3–3.1, P = 0.0028), while no differences were found in patients with persistent AF (77.9% vs 76.4%, 1.1, 0.7–1.7, P = 0.7065). Conclusion: PFA with the pentaspline catheter appears to be an effective treatment for AF in patients with HF. Freedom from AF and atrial arrhythmias post-PFA was highest in patients with paroxysmal AF and no history of HF, with no significant differences observed in persistent AF patients. Clinical Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/Identifier: NCT05617456.
- 17 March 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Open AccessPulsed field ablation for atrial fibrillation in patients with heart failure: insight from the ATHENA registry
Aims: Data on pulsed-field ablation (PFA) for atrial fibrillation (AF) in patients with heart failure (HF) are limited. To evaluate clinical outcomes of PFA in patients with AF and HF, stratified by HF subtype. Methods and Results: Consecutive patients undergoing first-time pentaspline PFA within the ATHENA registry were analyzed. Patients were stratified into three groups: no HF, HF with preserved ejection fraction (HFpEF, LVEF ≥50%), and HF with mildly reduced or reduced EF (HFmrEF/rEF, LVEF 30 s after a 2-month blanking period. AAD use was left to physician discretion. Among 1,224 patients included (68.5% with paroxysmal AF and 31.5% with persistent AF), 176 (14.4%) had HF: 40 (3.3%) with HFpEF and 136 (11.1%) with HFmrEF/rEF. The Kaplan-Meier estimated freedom from any atrial arrhythmias at 1-year follow-up was 79.9%, with higher rate in the no-HF group (81.0%) vs the HF group (73.3%, HR = 1.5, 95% CI: 1.1–2.1, P = 0.0133). Considering separately paroxysmal and persistent AF form, paroxysmal AF patients with no sign of HF showed significantly higher freedom from atrial arrhythmias (82.2%) than patients with HF (68.6%, 2.0, 1.3–3.1, P = 0.0028), while no differences were found in patients with persistent AF (77.9% vs 76.4%, 1.1, 0.7–1.7, P = 0.7065). Conclusion: PFA with the pentaspline catheter appears to be an effective treatment for AF in patients with HF. Freedom from AF and atrial arrhythmias post-PFA was highest in patients with paroxysmal AF and no history of HF, with no significant differences observed in persistent AF patients. Clinical Trial Registration: Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice (ATHENA). URL: http://clinicaltrials.gov/Identifier: NCT05617456.
- Open Access
- 26 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (3)
Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry
Aims: Occupational exposure to ionizing radiation in electrophysiology may significantly affect the careers of women of reproductive age. The aim of the STOOP registry was to quantify the estimated yearly occupational radiation exposure of female electrophysiologists of reproductive age performing consecutive radiofrequency catheter ablation (RFCA) for supraventricular tachycardia (SVT) adopting a fluoroscopy-minimization strategy. Methods: Twelve European centres participated. All procedures were performed with a fluoroscopy-minimization strategy, guided by 3D mapping systems and following the As Low As Reasonably Achievable (ALARA) principles. Results: A total of 710 RFCA procedures were performed by 32 operators (mean age38 ± 7 years). Mean procedure time was 80 ± 35 min, with a mean fluoroscopy time of 51 ± 153 s. The mean operator annual dose–area product (DAP) was 46.7 ± 79.5 Gy·cm², corresponding to an estimated mean annual effective dose of 9.34 ± 15.9 µSv. In no case did the yearly effective dose reach the 1 mSv occupational limit for pregnancy. The mean DAP did not differ among operators and was unaffected by operator experience or annual procedure volume. Conclusion: Performing SVT ablation with a fluoroscopy-minimization strategy results in operator radiation exposure far below the 1 mSv foetal dose constraint applicable once pregnancy is declared, irrespective of operator experience or case volume. These findings support the safety of continuing electrophysiology activity for women of reproductive age under modern fluoroscopy-free workflows.
- 26 February 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (3)
Open AccessFluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry
Aims: Occupational exposure to ionizing radiation in electrophysiology may significantly affect the careers of women of reproductive age. The aim of the STOOP registry was to quantify the estimated yearly occupational radiation exposure of female electrophysiologists of reproductive age performing consecutive radiofrequency catheter ablation (RFCA) for supraventricular tachycardia (SVT) adopting a fluoroscopy-minimization strategy. Methods: Twelve European centres participated. All procedures were performed with a fluoroscopy-minimization strategy, guided by 3D mapping systems and following the As Low As Reasonably Achievable (ALARA) principles. Results: A total of 710 RFCA procedures were performed by 32 operators (mean age38 ± 7 years). Mean procedure time was 80 ± 35 min, with a mean fluoroscopy time of 51 ± 153 s. The mean operator annual dose–area product (DAP) was 46.7 ± 79.5 Gy·cm², corresponding to an estimated mean annual effective dose of 9.34 ± 15.9 µSv. In no case did the yearly effective dose reach the 1 mSv occupational limit for pregnancy. The mean DAP did not differ among operators and was unaffected by operator experience or annual procedure volume. Conclusion: Performing SVT ablation with a fluoroscopy-minimization strategy results in operator radiation exposure far below the 1 mSv foetal dose constraint applicable once pregnancy is declared, irrespective of operator experience or case volume. These findings support the safety of continuing electrophysiology activity for women of reproductive age under modern fluoroscopy-free workflows.
- Open Access
- 6 November 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Management of device-detected subclinical atrial fibrillation: a European Heart Rhythm Association survey
Aims: Device-detected subclinical atrial fibrillation (DDAF) is increasingly documented either with implantable cardiac electronic devices (CIED) or with consumer-based mobile or wearable monitors. We aimed to investigate phisician's reaction to DDAF, which management is still matter of debate. Methods: This is a physician-based survey with 24 multiple-choice questions. Results: A total of 222 physicians from 46 countries responded the survey. DDAF is frequent, occurring in >10% of CIEDs follow-up for 37% of respondents. Oral anticoagulation is prescribed according to CHA2DS2-VA and AF duration; 34% of the respondents initiate anticoagulation with AF >24 h, 26% with AF >6 h, and 15% with AF >5–6 min. Respondents from non-European countries and Mediterranean Europe are more likely to prescribe diagnostic exams and therapy than respondents from North Europe. Systematic long-term AF screening with implantable loop recorder (ILR) after cryptogenic stroke ranges from 43 ± 27% of ILR implanted for that purpose in Mediterranean countries to 10 ± 20% in North Europe. The majority of responders recommends the use of consumer-based devices to screen for AF mainly in specific situations (undiagnosed palpitations, ischaemic stroke, or AF burden monitoring) and not routinely, just according to CHA2DS2-VA or age. Conclusion: AF screening is not routinely performed, either in primary or secondary prevention of stroke. Device-detected AF is not uncommon and generally managed based on thromboembolic risk and duration of episodes; the cut-offs of AF duration, global burden, and number of episodes are yet to be determined in terms of role and clinical value. Clinicians’ approaches to subclinical AF remain heterogeneous.
- 6 November 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessManagement of device-detected subclinical atrial fibrillation: a European Heart Rhythm Association survey
Aims: Device-detected subclinical atrial fibrillation (DDAF) is increasingly documented either with implantable cardiac electronic devices (CIED) or with consumer-based mobile or wearable monitors. We aimed to investigate phisician's reaction to DDAF, which management is still matter of debate. Methods: This is a physician-based survey with 24 multiple-choice questions. Results: A total of 222 physicians from 46 countries responded the survey. DDAF is frequent, occurring in >10% of CIEDs follow-up for 37% of respondents. Oral anticoagulation is prescribed according to CHA2DS2-VA and AF duration; 34% of the respondents initiate anticoagulation with AF >24 h, 26% with AF >6 h, and 15% with AF >5–6 min. Respondents from non-European countries and Mediterranean Europe are more likely to prescribe diagnostic exams and therapy than respondents from North Europe. Systematic long-term AF screening with implantable loop recorder (ILR) after cryptogenic stroke ranges from 43 ± 27% of ILR implanted for that purpose in Mediterranean countries to 10 ± 20% in North Europe. The majority of responders recommends the use of consumer-based devices to screen for AF mainly in specific situations (undiagnosed palpitations, ischaemic stroke, or AF burden monitoring) and not routinely, just according to CHA2DS2-VA or age. Conclusion: AF screening is not routinely performed, either in primary or secondary prevention of stroke. Device-detected AF is not uncommon and generally managed based on thromboembolic risk and duration of episodes; the cut-offs of AF duration, global burden, and number of episodes are yet to be determined in terms of role and clinical value. Clinicians’ approaches to subclinical AF remain heterogeneous.
- Open Access
- 2 September 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (10) , 2791-2792
RE: Performance of electrophysiology procedures at an academic medical center amidst the 2020 coronavirus (COVID‐19) pandemic by Rubin et al.
- 2 September 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (10) , 2791-2792
Open AccessRE: Performance of electrophysiology procedures at an academic medical center amidst the 2020 coronavirus (COVID‐19) pandemic by Rubin et al.
- 19 February 2018
- Published by Wiley in Echocardiography
- Vol. 35 (6) , 834-840
Angiography vs transesophageal echocardiography‐guided patent foramen ovale closure: A propensity score matched analysis of a two‐center registry
Objectives: The purpose of this study is to compare the long‐term outcomes of patent foramen ovale (PFO) closure using angiography or transesophageal echocardiography as procedural guidance.Background: The interventional treatment is emerging as a safe and efficient option for patients with high likelihood of PFO‐related cryptogenic stroke and high risk of recurrence. The “gold‐standard” guidance technique remains an issue.Methods: Two cohorts of patients undergoing PFO closure for cryptogenic stroke in two catheterization laboratories of the same institution, using similar inclusion criteria but different guidance, were compared with propensity score matching.Results: A total of 374 patients were enrolled, 161 in Angio‐group and 213 in Echo‐group. No difference was detected in the procedural complication rate. In Angio‐group, radiological exposure (P = .001) and 6‐month residual shunt (16.8% vs 8.0%, P = .015) were higher. After a mean follow‐up of 41 ± 30 months, 28 patients (7.5%) presented any adverse event (death, recurrent cerebral ischemia, device‐related complications, reintervention), with a higher rate in Angio‐group (13.0% vs 3.3%, P = .001), mainly due to repeated percutaneous intervention (10.6% vs 1.4%, P = .001). The results were confirmed after propensity score matching (118 patients/group). The rate of recurrent cerebral ischemia was 1.9% and was not significantly different in the two groups. Intra‐procedural guidance and atrial septum aneurysm were independent predictors of the composite primary endpoint (OR 1.2, P = .016).Conclusions: The use of intra‐procedural transesophageal echocardiography (TEE) guidance for PFO closure allows lower residual shunt rate, radiological exposure, and adverse events, mainly driven by a significant reduction in percutaneous reintervention.
- 19 February 2018
- Published by Wiley in Echocardiography
- Vol. 35 (6) , 834-840
Angiography vs transesophageal echocardiography‐guided patent foramen ovale closure: A propensity score matched analysis of a two‐center registry
Objectives: The purpose of this study is to compare the long‐term outcomes of patent foramen ovale (PFO) closure using angiography or transesophageal echocardiography as procedural guidance.Background: The interventional treatment is emerging as a safe and efficient option for patients with high likelihood of PFO‐related cryptogenic stroke and high risk of recurrence. The “gold‐standard” guidance technique remains an issue.Methods: Two cohorts of patients undergoing PFO closure for cryptogenic stroke in two catheterization laboratories of the same institution, using similar inclusion criteria but different guidance, were compared with propensity score matching.Results: A total of 374 patients were enrolled, 161 in Angio‐group and 213 in Echo‐group. No difference was detected in the procedural complication rate. In Angio‐group, radiological exposure (P = .001) and 6‐month residual shunt (16.8% vs 8.0%, P = .015) were higher. After a mean follow‐up of 41 ± 30 months, 28 patients (7.5%) presented any adverse event (death, recurrent cerebral ischemia, device‐related complications, reintervention), with a higher rate in Angio‐group (13.0% vs 3.3%, P = .001), mainly due to repeated percutaneous intervention (10.6% vs 1.4%, P = .001). The results were confirmed after propensity score matching (118 patients/group). The rate of recurrent cerebral ischemia was 1.9% and was not significantly different in the two groups. Intra‐procedural guidance and atrial septum aneurysm were independent predictors of the composite primary endpoint (OR 1.2, P = .016).Conclusions: The use of intra‐procedural transesophageal echocardiography (TEE) guidance for PFO closure allows lower residual shunt rate, radiological exposure, and adverse events, mainly driven by a significant reduction in percutaneous reintervention.